Mark P. Guerin
2021
In 2021, Mark P. Guerin earned a total compensation of $1.3M as Chief Financial Officer at Onconova Therapeutics, a 109% increase compared to previous year.
Compensation breakdown
| Bonus | $149,200 |
|---|---|
| Option Awards | $192,688 |
| Salary | $400,000 |
| Stock Awards | $528,430 |
| Other | $29,202 |
| Total | $1,299,520 |
Guerin received $528.4K in stock awards, accounting for 41% of the total pay in 2021.
Guerin also received $149.2K in bonus, $192.7K in option awards, $400K in salary and $29.2K in other compensation.
Rankings
In 2021, Mark P. Guerin's compensation ranked 7,818th out of 12,415 executives tracked by ExecPay. In other words, Guerin earned more than 37.0% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 7,818 out of 12,415 | 37th |
Division Manufacturing | 3,453 out of 5,505 | 37th |
Major group Chemicals And Allied Products | 1,536 out of 2,375 | 35th |
Industry group Drugs | 1,365 out of 2,096 | 35th |
Industry Pharmaceutical Preparations | 1,009 out of 1,546 | 35th |
Source: SEC filing on May 25, 2022.
Guerin's colleagues
We found two more compensation records of executives who worked with Mark P. Guerin at Onconova Therapeutics in 2021.